Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Most security teams think of NTFS junctions and symbolic links as niche file system features. They let one directory point to another, like a shortcut that the OS treats as real. They exist for ...

Recursion Pharmaceuticals combines artificial intelligence, automation, and biotechnology research across multiple ...

Recursive self-improvement AI now has a co-evolving evaluator: a Cambridge and NVIDIA preprint introduces the Red Queen Gödel ...

Ben Taylor, CFO of Recursion, here with us. Thanks so much for joining us. Sure. Great. And first of all, thanks for having us here, Tommie. This is always a terrific conference and great to be here.

Recursion Pharmaceuticals (NasdaqGS:RXRX) reported positive early clinical data from its AI driven drug discovery programs. The company highlighted progress in oncology and rare disease candidates in ...

Recursion Pharmaceuticals is trying to prove that AI’s next big winner can also come from biotech, and not just from the tech ...

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new investment opportunities through TipRanks' ...

The rise of AI has brought an avalanche of new terms and slang. Here is a glossary with definitions of some of the most ...